Compare Summit Therapeutics Inc (SMMT) vs Vanguard Value Index Fund ETF (VTV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs Vanguard Value Index Fund ETF — how do they compare? Summit Therapeutics Inc trades at $13.72 (market cap $10.48B), while Vanguard Value Index Fund ETF trades at $217. The key difference: Vanguard Value Index Fund ETF is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| SMMT | VTV | |
|---|---|---|
Market Cap | $10.48B | — |
Sector | Health | — |
52-Week High | $29.32 | $220.51 |
52-Week Low | $13.05 | $175.51 |
Enterprise Value | $9.90B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $13.50, down 2.24% on the day, reflecting ongoing volatility. The company reported a net loss of $1.08 billion for 2025, with negative ROE and ROA, but recent news includes the $105 million divestiture of ridinilazole to sharpen its oncology focus. Technical indicators are bearish, though RSI suggests potential oversold conditions. Analyst consensus remains optimistic with a $15.57 price target and 66.7% buy ratings.
The outlook hinges on clinical success of its lead oncology candidate, ivonescimab, which showed promising survival data. Key risks include high cash burn, binary drug trial outcomes, and shareholder litigation. The stock offers high-risk, high-reward potential for investors betting on pipeline success, but requires careful risk management due to financial losses and volatility.
VTV trades at $216.94, down 0.45% on the day, with a neutral technical signal and bullish moving averages. Recent news highlights its role as a stability-focused ETF amid AI sector volatility, with a 16% year-to-date gain. The fund's low expense ratio and value-oriented portfolio attract investors rotating away from tech.
The outlook for VTV hinges on continued value stock outperformance and Federal Reserve policy. Risks include inflation sensitivity and tech sector rebounds. Analyst sentiment is balanced, with the ETF positioned for defensive growth but vulnerable to macroeconomic shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About Vanguard Value Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the CRSP US Large Cap Value Index, a broadly diversified index predominantly made up of value stocks of large US companies. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VTV →
